Search Results - "Epstein, R. J."

Hanle effect measurements of spin lifetimes in InAs self-assembled quantum dots.

Authors: Epstein, R. J. Fuchs, D. T. Schoenfeld, W. V.

Source: Applied Physics Letters; February 5 2001, Vol. 78 Issue 6, p733-735, 3p

Anisotropic interactions of a single spin and dark-spin spectroscopy in diamond.

Authors: Epstein, R. J. Mendoza, F. M. Kato, Y. K. et al.

Source: Nature Physics. Nov2005, Vol. 1 Issue 2, p94-98. 5p. 4 Graphs.

Death in The New York Times: the price of fame is a faster flame.

Authors: EPSTEIN, C. R. EPSTEIN, R. J.

Source: QJM: An International Journal of Medicine. Jun2013, Vol. 106 Issue 6, p517-521. 5p. 4 Charts.

This result is not displayed to guests.
Login for full access.

Tumor resensitization to erlotinib following brief substitution of cetuximab.

Authors: Epstein, R. J. Leung, T. W.

Source: Cancer Chemotherapy & Pharmacology. Nov2008, Vol. 62 Issue 6, p1111-1112. 2p. 1 Graph.

"Leaving town" versus "taking leave": the case for re-thinking academic leave restrictions.

Authors: Epstein, R. J.¹ repstein@hku.hk

Source: Postgraduate Medical Journal. Dec2005, Vol. 81 Issue 962, p732-733. 2p.

Resolution of paraneoplastic immune thrombocytopenia following everolimus treatment for metastatic renal cell carcinoma.

Authors: Zheng, S. Chan, H. Epstein, R. J. et al.

Source: Internal Medicine Journal. Jun2015, Vol. 45 Issue 6, p666-669. 4p. 1 Graph.

Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis.

Authors: Brungs, D Chen, J Masson, P et al.

Source: Prostate Cancer & Prostatic Diseases. Jun2014, Vol. 17 Issue 2, p105-111. 7p.

Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer.

Authors: Wong, H. Lau, S. Yau, T. et al.

Source: British Journal of Cancer. 4/27/2010, Vol. 102 Issue 9, p1391-1396. 6p. 1 Diagram, 4 Charts, 1 Graph.

Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.

Authors: Hsu, C.-H. Yang, T.-S. Hsu, C. et al.

Source: British Journal of Cancer. 3/15/2010, Vol. 102 Issue 6, p981-986. 6p. 3 Charts, 1 Graph.

Review article: current management of metastatic colorectal cancer – the evolving impact of targeted drug therapies.

Authors: YAU, T. CHAN, P. Ching CHAN, Y. et al.

Source: Alimentary Pharmacology & Therapeutics. Jun2008, Vol. 27 Issue 11, p997-1005. 9p. 2 Diagrams, 1 Chart.

Towards scaling up trapped ion quantum information processing.

Authors: Leibfried, D. Wineland, D. J. Blakestad, R. B. et al.

Source: Hyperfine Interactions. Dec2006, Vol. 174 Issue 1-3, p1-7. 7p. 2 Diagrams.

Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells.

Authors: Huang, G.C. Hobbs, S. Walton, M et al.

Source: British Journal of Cancer. 4/8/2002, Vol. 86 Issue 7, p1104-1109. 6p.

Trapped Atomic Ions and Quantum Information Processing.

Authors: Wineland, D. J. Leibfried, D. Bergquist, J. C. et al.

Source: AIP Conference Proceedings. 2006, Vol. 869 Issue 1, p103-110. 8p. 1 Diagram.

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy.

Authors: Campone, M. Bondarenko, I. Brincat, S. et al.

Source: Annals of Oncology. Mar2012, Vol. 23 Issue 3, p610-617. 8p. 1 Diagram, 3 Charts, 4 Graphs.

Bevacizumab-based therapy for advanced small bowel adenocarcinoma.

Authors: Tsang, H. Yau, T. Khong, P. L. et al.

Source: Gut (0017-5749). Nov2008, Vol. 57 Issue 11, p1631-1632. 2p.

Has discovery-based cancer research been a bust?

Authors: Epstein RJ; Department of Oncology, Clinical Cancer Informatics & Research Centre, The Kinghorn Cancer Centre, Sydney, Australia, repstein@stvincents.com.au.

Source: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2013 Nov; Vol. 15 (11), pp. 865-70. Date of Electronic Publication: 2013 Sep 04.

Publication Type: Journal Article

Journal Info: Publisher: Springer Italia Country of Publication: Italy NLM ID: 101247119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1699-3055 (Electronic) Linking ISSN: 1699048X NLM ISO Abbreviation: Clin Transl Oncol Subsets: MEDLINE

A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer.

Authors: Sternberg CN Saad F Graff JN et al.

Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2020 Feb; Vol. 31 (2), pp. 257-265. Date of Electronic Publication: 2019 Dec 23.

Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

The threat that dare not speak its name: human extinction.

Authors: Epstein RJ Zhao Y

Source: Perspectives in biology and medicine [Perspect Biol Med] 2009 Winter; Vol. 52 (1), pp. 116-25.

Publication Type: Journal Article

Journal Info: Publisher: Johns Hopkins University Press Country of Publication: United States NLM ID: 0401132 Publication Model: Print Cited Medium: Print ISSN: 0031-5982 (Print) Linking ISSN: 00315982 NLM ISO Abbreviation: Perspect Biol Med Subsets: MEDLINE

A case of mixed adult Wilms' tumour and angiosarcoma responsive to carboplatin, etoposide and vincristine (CEO).

Authors: Yau T Leong CH Chan WK et al.

Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2008 Apr; Vol. 61 (4), pp. 717-20. Date of Electronic Publication: 2007 Jun 15.

Publication Type: Case Reports; Journal Article

Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0344-5704 (Print) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE